usculoskeletal pain is a common reason to seek health care, and a national initiative has provided guidance on priorities for improving management of this costly and disabling condition. 33 Two elements stressed in progressive pain-management strategies are earlier nonpharmacological treatment 13, 44 and enhancement of personalized/tailored care options. 33 Physical therapists can meet the demands of these initiatives by developing concise assessment tools to aid in clinical decision making for these elements. 27 In musculoskeletal pain management, there are 2 important components of almost every patient encounter: identification of symptoms that may indicate coexisting systemic pathology 15 and consideration of pain-associated distress and coping styles. 49 These components are important to consider, because their results could alter an episode of care by indicating the need for additional diagnostic testing before starting traditional nonpharmacological treatment, 14, 28 either alone or supplemented with principles of psychologically informed practice. 5, 31, 42 The Orthopaedic Physical Therapy-Investigator Network (OPT-IN) was formed to develop and validate concise assessment tools for individuals with a primary complaint of neck, shoulder, low back, or knee pain. The OPT-IN provided the clinical infrastructure necessary to recruit for U U STUDY DESIGN: Observational, prospective cohort.
U U BACKGROUND:
Musculoskeletal pain is a common reason to seek health care, and earlier nonpharmacological treatment and enhancement of personalized care options are 2 high-priority areas. Validating concise assessment tools is an important step toward establishing better care pathways.
U U OBJECTIVES:
To determine the predictive validity of Optimal Screening for Prediction of Referral and Outcome (OSPRO) tools for individuals with neck, low back, shoulder, or knee pain.
U U METHODS:
A convenience sample (n = 440) was gathered by Orthopaedic Physical Therapy-Investigator Network clinics (n = 9). Participants completed demographic, clinical, and comorbidity questionnaires and the OSPRO tools, and were followed for 12-month outcomes in pain intensity, region-specific disability, quality of life, and comorbidity change. Analyses predicted these 12-month outcomes with models that included the OSPRO review-of-systems (OSPRO-ROS) and yellow flag (OSPRO-YF) tools and planned covariates (accounting for comorbidities and established demographic and clinical factors).
U U RESULTS:
The 10-item OSPRO-YF tool (baseline and 4-week change score) consistently added to predictive models for 12-month pain intensity, region-specific disability, and quality of life. The 10-item OSPRO-ROS tool added to a predictive model for quality of life (mental summary score), and 13 additional items of the OSPRO-ROS+ tool added to prediction of 12-month comorbidity change. Other consistent predictors included age, race, income, previous episode of pain in same region, comorbidity number, and baseline measure for the outcome of interest.
U U CONCLUSION:
The OSPRO-ROS and OSPRO-YF tools statistically improved prediction of multiple 12-month outcomes. The additional variance explained was small, and future research is necessary to determine whether these tools can be used as measurement adjuncts to improve management of musculoskeletal pain. J Orthop Sports Phys Ther 2018;48 (6) : [460] [461] [462] [463] [464] [465] [466] [467] [468] [469] [470] [471] [472] [473] [474] [475] . Epub 7 Apr 2018 . doi:10.2519 /jospt.2018 the Optimal Screening for Prediction of Referral and Outcome (OSPRO) development and validation cohorts. The OSPRO cohort studies occurred in sequence, with the development cohort (a cross-sectional study for tool development) and the separately recruited validation cohort (a longitudinal study to test the predictive validity of the newly developed tools). The instruments were directly aligned with assessment of examination components that could influence a care episode. A review-of-systems (OSPRO-ROS) tool was developed for assessing symptoms of systemic pathology, 19 and a yellow flag (OSPRO-YF) tool was developed to assess psychosocial aspects of pain vulnerability and resilience. 39 Details on the OSPRO-ROS and OSPRO-YF tools have been previously reported 19 ,39 and will be described in more detail in the Methods section.
Though the development of the OS-PRO-ROS and OSPRO-YF tools was encouraging, all prior work was done in a cross-sectional manner. 19, 39 Because longitudinal studies provide a more optimal design to test the capabilities of these tools and to determine their predictive validity for outcomes relevant to clinical decision making, the purpose of the current paper was to report the primary analyses of the OSPRO validation cohort in individuals with a primary complaint of neck, low back, shoulder, or knee pain. These analyses involved prediction of 12-month pain, quality of life, region-specific disability, and comorbidity outcomes. Predictive models were built to determine the contribution of the OSPRO tools to 12-month outcomes after demographic, clinical, and baseline variables were already considered. In addition, we analyzed the interaction between anatomical region and the OSPRO tools to determine whether the performance of the tool would vary based on the primary site of pain. This approach provided a relatively high bar to determine the predictive validity of the new tools, because the models included previously established predictive factors and anatomical region as planned covariates. Based on prior studies showing that change in psychological factors may improve outcome prediction for low back pain, 4, 26, 55, 57 4-week change in the OSPRO-YF tool was entered into the last step of the prediction models. Our primary hypotheses were that the OSPRO-YF tool would improve prediction of pain and disability outcomes, while the OSPRO-ROS tool would improve prediction of quality of life and comorbidity outcomes.
METHODS

Overview
T
he OSPRO validation cohort study was approved by the University of Florida Human Subjects Institutional Review Board, and all participants provided consent to participate in the study. A convenience sample was gathered by participating OPT-IN clinics (n = 9) for the months of December 2014 through December 2015. The OPT-IN clinics that participated in data collection represented 5 of 8 geographic regions in the United States, including the Mideast, Southeast, Great Lakes, Rocky Mountain states, and Far West. The majority of the patients (275/440, 62.5%) were recruited from clinics in the Southeast region. The New England, Plains, and Southwest regions were not represented. An attempt was made to achieve a balance of patients from urban and rural settings over the entire OPT-IN; however, for pragmatic reasons, that balance could not be provided within each geographic region. Methodological details for the OSPRO validation cohort have been previously reported in a cohort-profile paper. 20 The current paper presents an abbreviated version of the methods that allows for interpretation of the primary analyses.
Participants
Inclusion Criteria Physical therapists determined the eligibility of participants at the initial evaluation using matching criteria from the development cohort. 19, 39 Patients between 18 and 65 years of age were eligible to participate in this study if they (1) were seeking outpatient physical therapy treatment for musculoskeletal pain; (2) had primary complaints involving the cervical spine, lumbar spine, shoulder, or knee; and (3) were able to read and comprehend the English language (this criterion was necessary due to the large number of self-report forms). Exclusion Criteria Patients were excluded from study participation for any diagnosis indicative of (1) widespread chronic pain syndrome (eg, fibromyalgia or irritable bowel syndrome), (2) neuropathic pain syndrome (eg, complex regional pain syndrome or diabetic neuropathy), (3) psychiatric history (currently in care of mental health care provider or taking 2 or more prescription psychiatric medications), (4) cancer (currently receiving treatment for active cancer), or (5) neurological disorder (eg, stroke, spinal cord injury, or traumatic brain injury).
Baseline and follow-up data collection was conducted online at the clinic or at home (based on individual preference), and the participants completed all survey assessments on the study website. Eligible participants were directed to a secure, University of Florida-hosted website for the informed-consent process and baseline assessment. All assessments were selfreport and completed electronically by the participant in a deidentified manner.
Follow-ups were at 4 weeks, 6 months, and 12 months, and participants were notified of a pending assessment by an e-mail that directed them back to the study website to complete their follow-up assessment. If participants did not complete their follow-up assessment within 1 week of the first e-mail notification, then an additional e-mail reminder was sent each week for up to 3 weeks. Participants who were not responsive to any of these e-mail reminders were contacted by telephone. Only 12-month data were reported in this paper, and there are no plans to report the 6-month data separately. 9, 24 For analysis purposes, a comorbidity count was derived by adding a unique number of comorbidities reported (ie, similar comorbidities reported in both indices were only counted once). The number of comorbidities reported at baseline was used as a covariate.
Predictive Measures
OSPRO Tools
Review of Systems The OSPRO-ROS tool includes standard symptom descriptors previously used to aid in screening for potential systemic involvement. 19 It includes questions related to symptoms of the cardiovascular, gastrointestinal, endocrine, nervous, integumentary, pulmonary, and musculoskeletal systems that were identified based on their ability to predict any 1 positive response to a larger item bank. The accuracy of the 10-and 23-item versions of the OSPRO-ROS tool differed in predicting a positive response to the larger item bank 19 ; therefore, these versions were considered separately in predictive analyses. The OS-PRO-ROS tool was scored by summing the positive responses, which provided a potential range of 0 to 23 when all 23 items were used. Higher OSPRO-ROS scores indicate higher levels of red flag symptom complaints. In this analysis, we separated the 23 items to determine whether they uniquely contributed to outcomes of interest; therefore, OSPRO-ROS refers to the first 10 items of the tool and OSPRO-ROS+ refers to the additional 13 items. Yellow Flags The OSPRO-YF tool includes items from pain-vulnerability domains (negative affect and fear avoidance) and pain-resilience domains (positive affect and self-efficacy) to aid in the efficient identification of pain-associated psychological distress and coping. 39 The OSPRO-YF tool estimates scores for fulllength parent questionnaires with increased accuracy based on 10-and 17-item versions of the tool. The OSPRO-YF tool was considered in predictive analyses by testing the 10-item version and additional 7 items separately. 39 The OSPRO-YF tool was scored by summing all item responses from the original parent questionnaires on the original scale, with pain-resilience items reverse scored, providing a potential score range of 6 to 89 when all 17 items are used. Higher OSPRO-YF scores indicate higher psychological distress, as demonstrated by higher pain vulnerability and lower pain resilience.
Outcome Measures
Outcome measures were captured at baseline and at 12-month follow-up. The baseline value of a given measure was included in the corresponding prediction model for 12-month outcomes. Pain intensity was assessed with the 0-to-10 numeric pain-rating scale (NPRS), with 0 indicating no pain and 10 the worst pain imaginable. Participants rated their current pain intensity, as well as their best (lowest) and worst (highest) pain intensity over the past 24 hours. 6, 10, 35 The average of these 3 NPRS scores was used to represent pain intensity in these analyses.
Region-specific disability was assessed by participants completing 1 of the following questionnaires that matched the primary site of pain complaint: (1) Neck Disability Index, 53 (2) Oswestry Disability Questionnaire, 17 (3) shortened version of the Disabilities of the Arm, Shoulder and Hand questionnaire, 2 or (4) International Knee Documentation Committee Subjective Knee Evaluation Form. 34 The individual region-specific measures were included in the analysis as z scores due to different scaling, and were thus able to be included in the same predictive models, consistent with analyses from the OS-PRO development cohort. 7 The Medical Outcomes Study 8-Item Short-Form Health Survey was used as a general quality-of-life measure and reported as the corresponding Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. 18, 38 Comorbidity at 12 months was included as an outcome measure to determine change in disease burden and assessed in the same manner described in the Predictive Measures section.
Data Analysis
Our primary analyses assessed the accuracy of the OSPRO-ROS and OSPRO-YF tools in predicting 12-month outcomes. Separate general linear models were fitted for the continuous outcome measures of 12-month pain intensity, regionspecific disability, quality of life, and comorbidity, using the OSPRO tools as planned fixed effects. Before OS-PRO tools were considered, we entered planned covariates into each prediction model, including, for example, age, sex, race, income, employment, education, type of insurance, geographic region, pain location, pain duration, pain onset type, previous episode in same location, history of surgery, comorbidities, and the corresponding outcome measure at baseline (full set reported in TABLE 1 ). This modeling approach is consistent with other reports in the literature 3, 16, 25 and resulted in the following model structure, applied consistently for each outcome of interest: [ research report ] 8 Therefore, this paper reported results from completed cases, regression imputation, and inverse probability weighted. Presenting the results in this manner remained true to the original analysis plan, while also presenting models that appropriately accounted for loss to follow-up.
sidering that the data might not have been missing at random, we also performed regressions inversely weighted by inclusion (nonmissing) probability, which was estimated based on logistic regressions with logit link and predictors that included age, education, type of insurance, pain onset type, and baseline demodels to investigate the specificity of their use based on primary site of pain complaint. Predictive analyses were first conducted with completed cases in full (all covariates) and parsimonious (backward-selection) models. Missing 12-month outcomes were then accounted for using regression imputation. 47 Con- Region-specific disability (z score)* .032
[ research report ]
Power Analysis
There are no uniform standards for determining sample size in cohort studies.
For the OSPRO studies, sample-size estimates were based on precision for the assessment tools. The sample size was calculated so that 95% confidence intervals for the accuracy of predicting the 23-item version of the OSPRO-ROS tool from the abbreviated 10-item version would have a maximum width of ±5%. Specifically, we required that sample size 
RESULTS
Recruitment and Follow-up Summary
A descriptive summary of the OS-PRO validation cohort is reported in TABLE 1, and additional data are available in the cohort profile paper. 20 A total of 440 participants completed baseline measures with primary complaints of neck (n = 98, 22.3%), shoulder (n = 107, 24.3%), low back (n = 118, 26.8%), or knee (n = 117, 26.6%) pain. A total of 279 (63.4%) participants completed the 12-month follow-up with primary complaints of neck (n = 59, 21.1%), shoulder (n = 66, 23.7%), low back (n = 72, 25.8%), or knee (n = 82, 29.4%) pain. While there were no differences in follow-up rates by anatomical region, there were several differences between those who completed the 12-month follow-up and those who did not (TABLE 1) .
Those who completed the follow-up were more likely to be older, have higher income, and have completed higher levels of education. There were differences in insurance type, clinic site, and onset of symptoms based on 12-month follow-up. Finally, those who completed the followup had lower scores on the OSPRO-YF, neck disability, pain intensity, and composite z score for region-specific disability. Those who did not complete the follow-up for this study were more likely to have lower income and education levels, to be uninsured or on disability, to be covered by Medicaid or workers' compensation, and to be experiencing higher pain and pain-associated distress. All variables reported in TABLE 1 were planned as covariates, so no additional covariates were added to the prediction models based on differences in follow-up rates.
Overall Model Performance
Overall performance for completed cases, regression imputation, and inverse probability-weighted models is summarized in TABLE 2, and individual predictors across these models are summarized in There was a consistent pattern in the prediction of 12-month pain, disability, and quality-of-life outcomes. The baseline value of the outcome of interest explained most of the additional variance, after accounting for demographic and clinical variables. The 10-item version of the OSPRO-YF tool explained variance beyond baseline scores, and the 10-item version of the OSPRO-ROS tool explained only the additional variance in MCS scores. The additional amount of variance explained at baseline by OS-PRO tools was small (increment range, 0.01-0.07). When the 4-week change in the 10-item OSPRO-YF tool was added to prediction models, it explained additional variance in 12-month pain, disability, and quality-of-life outcomes. Again, the overall amount of variance added was smaller than change scores (increment range, 0.04-0.07).
The pattern for predicting 12-month comorbidity change differed from the other outcome measures. Baseline number of comorbidities still explained the most additional variance after accounting for demographic and clinical variables; however, only the 13 additional items from the OSPRO-ROS+ tool explained variance in the models predicting 12-month comorbidity change.
Individual Predictors of Outcome
Parsimonious models were used to identify individual predictors, because they provided a conservative estimate of the overall model's predictive ability (parsimonious models had the lowest total variance explained) (TABLE 2). Parsimonious models were deemed appropriate for identifying individual predictors due to a lower-than-anticipated follow-up rate at 12 months, which suggests that the full models would have been overfitted had all the covariates been included. Finally, we wanted to preserve the efficiency in identifying (ie, reporting the fewest) individual predictors and to avoid overreporting individual predictors. Fewer individual predictors make the building of future risk models easier by better prioritizing the collection of clinical data. Results from completed cases and regression imputation models were reported to allow for direct comparisons of model stability.
Model parameters for individual predictors are provided in detail in TABLE 4 (pain intensity and region-specific disability), TABLE 5 (quality of life), and TABLE 6 (comorbidity). The estimates provided in TABLES 4 through 6 represent how much the outcome variable would be expected to change per 1 unit of change in a given predictor variable. For example, for the 12-month pain intensity outcomes in TABLE 4, the estimate for "previous episode" as a categorical predictor is 0.83 (completed-cases model). This means that a response of yes to "previous episode" would increase the expected 12-month pain intensity score by an additional 0.83 points on the NPRS compared to a response of no. As another example from TABLE 4, baseline pain intensity is a continuous predictor with an estimate of 0.41 (completed-cases model). This means that a baseline pain intensity score of 6 would be predicted to be 2.05 points higher (5 × 0.41) at 12 months on the NPRS compared to a baseline pain intensity score of 1. A summary of individual predictors for each outcome is provided below. 12-Month Pain Intensity Previous episode in same region, baseline pain in-tensity, and the OSPRO-YF tool (10-item and 4-week change) were predictors in the inverse probability-weighted model (TABLE 4). These predictors matched the completed-cases model, while the regression imputation model also included educational level.
12-Month Region-Specific Disability
The inverse probability-weighted model included sex, race, comorbidity, baseline score, and OSPRO-YF tool (10-item and 4-week change) as individual predictors (TABLE 4). These predictors matched the completed-cases model. The regression imputation model included different demographic factors for predictors (eg, age and previous episode) and also considered anatomical region. The nature of the interaction indicated that prediction of disability outcomes at the shoulder region differed from those at the knee; otherwise, individual predictors matched those of the other models. 12-Month PCS Race, comorbidity, baseline PCS score, and the OSPRO-YF tool (10-item and 4-week change) were predictors in the inverse probability-weighted model ( The completed-cases model included only the baseline number of comorbidities and 13 additional items of the OSPRO-ROS+, and the regression imputation model included age, the baseline number of comorbidities, and 13 additional items of the OSPRO-ROS+.
DISCUSSION
A nalyses from the OSPRO validation cohort provided additional information on the use of concise assessment tools for prediction of musculoskeletal pain outcomes. The 10-item OSPRO-YF added statistically to the prediction of 12-month pain intensity, disability, and quality of life (physical and mental), a finding consistent with other concise tools for pain-associated distress (eg, the Örebro Musculoskeletal Pain Questionnaire 32, 41 and STarT Back Tool 29, 30 ). The 10-item OSPRO-ROS tool added statistically to the prediction of 12-month quality-of-life (mental) outcomes, while the 13-item OSPRO-ROS+ tool added statistically to the prediction of comorbidity status outcomes. The present study's findings on the OSPRO-ROS and OSPRO-ROS+ are novel, as there are no other tools available that we are aware of for direct comparison, and these data provide preliminary support for the predictive validity of these tools. All predictive models included demographic, clinical, and baseline variables as planned covariates, consistent with previous modeling strategies. 3, 21, 25 The OSPRO tools added a relatively small amount of variance to models containing covariates (ie, demographic and clinical factors, comorbidity, and baseline outcome scores), as in another report that focused on psychological measures. 16 Therefore, the OSPRO tools may have limited potential to enhance clinical decision making, when considered in conjunction with demographic variables and baseline outcome scores. The OSPRO tools are intentionally concise and consistently contributed to outcome prediction across a variety of domains in the parsimonious prediction models. Therefore, these tools could be useful measurement adjuncts for health systems developing clinical pathways to determine the appropriateness of nonpharmacological pain management, 44 to facilitate the delivery of psychologically informed treatment options, 42 and to assess the impact of disease burden on patient-management strategies. 48 However, the individual clinical relevance (if any) of the OSPRO tools will need to be determined in follow-up studies in additional cohorts.
The 10-item OSPRO-YF tool consistently contributed a small amount of additional variance to the predictive models for 12-month pain intensity, 
region-specific disability, and qualityof-life (mental and physical) outcomes. This finding shows a predictive ability similar to that of the aforementioned assessment tools (eg, Örebro Musculoskeletal Pain Questionnaire 32,41 and STarT Back Tool 29, 30 ), and a recent study suggests that it is unlikely that any single screening tool would be superior for prediction when compared with other screening tools. 37 A few caveats deserve mention in interpreting results from this cohort. First, the OSPRO-YF tool is predictive of multiple outcome domains, while the other assessment tools tend to have stronger predictive capabilities for functional outcomes. 36 Second, the OSPRO-YF tool included items for pain resilience, a dimension not captured by the other tools but that may be relevant for predicting pain-related outcomes. Third, the OS-PRO-YF tool can be used as a total score (as in the analyses of the present study) or as estimate scores of the 11 full-length parent questionnaires for negative mood, fear avoidance, and positive coping style (as in the development paper 39 ). However, we acknowledge that the predictive contributions of the OSPRO tools to outcomes were small in magnitude and that additional research must be completed to provide informed recommendations for clinical use.
The contribution of the 10-item OS-PRO-YF 4-week change score to outcome prediction expands the concept of treatment monitoring for individuals with neck, shoulder, and knee pain. Considering an immediate change in pain-associated psychological distress may improve prediction of longer-term clinical outcomes. Treatment monitoring via change in psychological measures has been established for patients with low back pain. 26, 43, 50, 55, 56 In this cohort, we considered the OSPRO-YF tool for its treatment-monitoring capacity across several other musculoskeletal pain conditions. The 4-week change in the 10-item OSPRO-YF tool consistently contributed a small amount of additional variance to the prediction of 12-month outcomes for pain intensity, region-specific disability, and quality of life. The contribution of the OSPRO-YF change score, while small in magnitude, was of equal weight to the baseline score for a given prediction model. This finding suggests that, to enhance outcome prediction via treatment monitoring, psychological assessments should be structured to capture baseline status and a follow-up measure, because they both equally contributed to the outcome of interest. The 10-item OSPRO-ROS tool was narrower in its predictive scope by being specific to 12-month quality of life (mental). The finding for MCS scores suggests that the OSPRO-ROS (short version) can be used in tandem with the OSPRO-YF tool for better accuracy on mental health outcomes. The 10-item OSPRO-ROS tool correlated with depressive symptoms in the cross-sectional development cohort, 19 and this was a corroborative finding in the longitudinal validation cohort. These findings suggest that, though the items of the OSPRO-ROS are focused on red flag symptomatology, there is a link between these symptoms and overall mental health status, even after other psychological factors are considered (by the OSPRO-YF tool in these analyses).
The additional 13 items from the OS-PRO-ROS+ contributed small amounts of additional variance to the prediction of 12-month comorbidity change. Red flag symptom assessment has traditionally been geared toward determining existing pathology, but this strategy has been questioned due to low accuracy. 14, 52 An alternate approach to red flag assessment is to determine the association with change in medical, health, or disease status. 19, 46 In these analyses, we focused on whether the 10-item OSPRO-ROS tool and the additional 13 items from the OSPRO-ROS+ were predictive of 12-month comorbidity change. Comorbidity status was selected because musculoskeletal pain burden may be exacerbated by the presence of multiple comorbid conditions, which can independently influence the trajectories of perceived health status, functional impairment, and disability. 45, 51, 54 As a result, there is surging interest in the implications that multiple comorbidities (ie, multimorbidity) have for individual patient care and decision making. 1 To better understand the impact of multimorbidity and to more clearly define who may be at risk for poor outcomes, physical therapists and other health care providers will need assessment tools that provide a reasonable estimate of future disease burden. Information on future disease burden can then be combined with other existing methods for predicting clinical outcomes, resulting in an approach that generates care pathways to address issues specific to multimorbidity. The additional 13 items of the OSPRO-ROS+ predicted 12-month comorbidity change, adding to models that already included the baseline number of comorbidities. This is an encouraging finding that could aid future clinical decision making for value-based care in musculoskeletal pain, 40, 48 but it will need to be investigated in additional studies for replication.
The OSPRO tools added statistically to the prediction of outcomes after considering baseline outcome scores, but contributions may have limited clinical relevance. For example, the baseline 10-item OSPRO-YF score (range, would have to vary by 30 points to correspond with a 2-point difference in 12-month pain intensity outcome. This suggests that the OSPRO-YF could be used to refine a prediction after an initial trajectory is determined by a baseline pain-intensity score. Large differences in In the case of the OSPRO-YF tool, the 4-week change score can be used to further refine outcome prediction, which may enhance its utility, but with the burden of additional measurement. Future utility of the OSPRO tools can only be determined by future studies that directly link their use to clinical decision making. These findings did indicate that the OSPRO tools can be used broadly across individuals with neck, shoulder, low back, and knee pain. The present study found little evidence of the influence of anatomical region on the OSPRO-YF and the OSPRO-ROS tools. These findings were similar to those of our previous work in depressive symptoms, 21 fear-avoidance beliefs, 22 and pain-associated distress. 7 The finding that the influence of psychological symptoms on clinical outcomes is not region dependent has been reported in other cohorts. 11, 12 However, the regression imputation analyses did indicate a potential for differences based on disability measures that are specific to anatomical region. For example, our analyses indicated that slightly higher 12-month disability scores would be expected for shoulder pain compared to knee pain, given the same baseline OSPRO-YF score. This finding, which suggests the need to consider anatomical specificity in yellow flag assessment, converges with the initial validation of a modified STarT Back Tool. 29 The reasons for these contrasting findings from the regression imputation models cannot be determined or resolved within this cohort. However, they do provide focus for future study in this area by determining whether OSPRO tool interpretation needs to be adjusted based on anatomical region when the outcome of interest is region-specific disability.
Primary limitations of the OSPRO validation cohort, including convenience sampling and lack of individual treatment parameters, have been described in the cohort profile paper. 20 Another primary limitation is that we did not include specific medical diagnoses or severity of injury in the predictive models; therefore, these predictive models may not be applicable when a specific medical diagnosis is a strong predictor of clinical outcomes. An additional limitation of this analysis was the follow-up rate of 63.4%, which was lower than anticipated. Furthermore, there were multiple differences between those who completed follow-up and those who did not. These predictive models may need to be adjusted to account for those participants who identify as nonwhite, report lower income and education levels, are uninsured, receive Medicaid or workers' compensation, and report higher levels of pain and pain-associated distress. To account for this lower-than-anticipated and differential follow-up rate, we were transparent in interpreting results from parsimonious models (to avoid reporting overfitted models) that accounted for the missing data (to avoid loss-to-follow-up bias). The completed-cases and imputed models most often showed very good convergence, but these analyses indicated that the prediction of comorbidity outcomes was most affected by the loss to follow-up. Another limitation is that all outcomes for these analyses were selfreported. Future studies should consider incorporating a corresponding physical performance measure and medical record verification of the 12-month comorbidity status. Finally, the present analysis did not weight the OSPRO-YF tool based on its different components (eg, negative affect, fear avoidance, and positive coping). Therefore, a limitation in interpreting the OSPRO-YF tool score is not knowing which individual components may be better targeted for intervention approaches or whether there are dominant components of the OSPRO-YF tool for predicting outcomes.
The OSPRO validation cohort generated several areas for future research. First, the musculoskeletal conditions recruited in this cohort were selected because they were highly prevalent and commonly treated by physical therapists in outpatient settings. Future study of the OSPRO tools in less prevalent patient groups is necessary to determine refinements to the existing tools. Second and specific to the OSPRO-ROS tool, there may be an interest in determining whether the tool can be used to identify the need for additional diagnostic testing. Although this direction was not our intent in the validation cohort, the OS-PRO-ROS tool could be investigated in appropriately designed future studies for improving diagnostic accuracy in identifying systemic pathology. Third and specific to the OSPRO-YF tool, future study should investigate whether relevant domains not originally included in the tool's development (eg, perceived injustice and optimism) would improve the predictive performance of the tool. Finally, the original OSPRO tool development did not include item response theory, and using such an analytical approach could generate different tools to compare performance in future predictive testing.
Future work should determine whether or how OSPRO tools may improve clinical decision making for musculoskeletal pain. The OSPRO tools could be used to direct tailored treatment options for higher painassociated psychological distress linked to poor outcomes or for symptom reports indicating increased disease burden. The current study was predictive, but future studies could investigate whether these tools may be used to identify responders via treatment-effect modification or to verify their use as treatment-monitoring tools via mediation analyses. Another area of future work is to incorporate the OS-PRO tools into existing electronic health records and/or patient registries. The OS-PRO tools provide a concise way to capture relevant risk-adjustment parameters that are often missing from large-scale data sets on musculoskeletal pain. Pragmatic use of these tools would allow for more precise estimates of their predictive capabilities for clinical outcomes and exploration of their ability to predict future health care utilization. For example, these tools could be used to identify patients who start in a nonpharmacological care pathway, then transition to higher-risk options like opioids, injections, or surgery. Earlier identification of these patients may allow for additional tailored strategies to prevent unwarranted utilization of highrisk, low-benefit treatments for musculoskeletal pain.
CONCLUSION
T he primary analyses from the OSPRO validation cohort demonstrated that the OSPRO tools added statistically to the prediction of 12-month outcomes for common musculoskeletal pain conditions. The 10-item OSPRO-YF tool, designed to assess negative mood, fear avoidance, and positivecoping styles, improved prediction of 12-month pain intensity, region-specific disability, and quality of life (physical and mental). The 10-item OSPRO-ROS tool, designed to assess red flag symptomatology, improved prediction of 12-month quality of life (mental). The additional 13 items from the OSPRO-ROS+ improved prediction of 12-month comorbidity status. The OSPRO tools contributed small amounts of variance to prediction models that included demographic and clinical factors, comorbidity, and baseline scores. The OSPRO validation cohort was not designed to be a definitive study, so future research is needed to determine whether these tools have a role in improving clinical decision making for better management of musculoskeletal pain. U
KEY POINTS FINDINGS:
The baseline score and 4-week change in the 10-item Optimal Screening for Prediction of Referral and Outcome yellow flag (OSPRO-YF) tool improved statistically the prediction of 12-month pain intensity, region-specific disability, and quality of life (physical and mental) outcomes. The baseline score of the 10-item Optimal Screening for Prediction of Referral and Outcome review-of-systems (OSPRO-ROS) tool statistically improved the prediction of 12-month quality of life (mental), and the additional 13 items in the OSPRO-ROS+ statistically improved the prediction of comorbidity change. IMPLICATIONS: The OSPRO tools can be used for baseline assessment and treatment monitoring for commonly occurring musculoskeletal conditions (ie, neck, shoulder, low back, or knee pain). The OSPRO tools contributed to outcome prediction, but their contribution to the models was small in magnitude. It is our assertion that the OSPRO tools may be used for directing care in painmanagement pathways that deliver early nonpharmacological treatments, psychologically informed approaches, or want to consider the impact of multimorbidity. CAUTION: The study sample was not recruited consecutively and there was high loss to follow-up; therefore, these results may not be entirely representative of patient populations. There is some evidence of anatomical specificity in these tools for predicting region-specific outcomes, which will need to be considered in future studies. Additional studies are needed to determine the utility of the OSPRO tools for clinical decision making.
